How to read a pharma income statement
Every dollar of revenue goes to four places:
| Line | What it pays for |
|---|---|
| Cost of sales | Making the product: manufacturing, raw materials, quality control, royalties. Often excludes amortization of acquired intangibles, which is shown separately. |
| Research and development (R&D) | Discovery, clinical trials, regulatory filings, and post-approval studies. |
| Acquired IPR&D | Upfront and milestone payments for in-licensed or acquired drug candidates that are not yet approved. These are expensed immediately under US GAAP. Some companies show it as a separate line; Merck includes it in R&D. |
| SG&A | Sales forces, marketing, medical affairs, market access, and corporate functions. Companies use different names, such as MS&A (Lilly) and SI&A (Pfizer). |
What remains, after amortization, restructuring, other income and expense, and tax, is profit. Profit then funds factories (capital spending), deals, dividends, and share buybacks, which appear in the cash flow statement.
All figures in this article are reported GAAP or IFRS figures for fiscal 2025, taken from each company’s earnings release. They are not the adjusted (non-GAAP or core) figures that companies highlight.
Five companies, five budgets
[Chart: Company 2025 earnings releases (GAAP; Roche IFRS, total revenues). AskDona calculations. See the live document for the chart.]
| Company (revenue) | Cost of sales | R&D | Acquired IPR&D | SG&A | Operating margin |
|---|---|---|---|---|---|
| Eli Lilly ($65.2B) | 17% | 20.5% | 4.5% | 17% | 40% |
| Merck ($65.0B) | 25% | 24% (incl. IPR&D) | in R&D | 16.5% | not shown (pre-tax 32%) |
| Roche (CHF 63.4B) | 26% | 21% | in R&D | 24% | 29% |
| Pfizer ($62.6B) | 26% | 17% | 2.6% | 22% | not shown (pre-tax 12%) |
| AbbVie ($61.2B) | 30% | 15% | 8.2% | 23% | 25% |
What the numbers show:
- R&D is the biggest single choice. It ranges from 15% at AbbVie to 24% at Merck. Lilly ($13.3 billion) and Merck ($15.8 billion) spend the most in dollars.
- Buying versus building. AbbVie spent $5.0 billion on acquired IPR&D and milestones, more than half its internal R&D. In effect, it buys much of its pipeline. Lilly ($2.9 billion) and Pfizer ($1.6 billion) also buy, but less in proportion.
- Selling costs about as much as researching. SG&A runs at 16 to 24% of revenue, close to R&D. Pfizer and AbbVie spend more on SG&A than on internal R&D.
- Product mix drives cost of sales. Lilly’s is only 17%, while AbbVie’s is 30%. Margins depend on which products sell most and on what each company includes in the line.
- Amortization from past deals weighs on profits. Pfizer carries $4.9 billion of amortization, a legacy of acquisitions, and $1.6 billion of restructuring. Its pre-tax margin is 12%, against Lilly’s 40% operating margin.
Below the income statement: factories, deals, and shareholders
Profit and cash flow fund three more choices:
| Company | Capital spending | Dividends | Buybacks | Largest 2025 deal |
|---|---|---|---|---|
| Eli Lilly | $7.8B (12% of revenue) | $5.4B | $4.1B | Verve Therapeutics, up to about $1.3B |
| Merck | $4.1B | $8.2B | $5.1B | Verona Pharma, about $10B |
| Roche | CHF 3.7B | CHF 8.4B | none | 89bio, $2.4B upfront plus contingent value rights (CVR) |
| Pfizer | $2.6B | $9.8B | none | Metsera, about $7.0B; about $8.8B of business development in total |
| AbbVie | $1.2B | $11.7B (19% of revenue) | $1.0B | Capstan Therapeutics, $2.1B |
Capital spending, dividends, and buybacks for the four US companies come from a secondary data provider (stockanalysis.com), not directly from the filings.
Three capital allocation models stand out:
- Build capacity (Lilly). Lilly’s capital spending of $7.8 billion is two to six times its peers’, and is larger than its buybacks. Capital spending pays for plants and equipment, so this points to an investment in manufacturing capacity.
- Return cash (AbbVie, Pfizer). At AbbVie ($11.7 billion) and Pfizer ($9.8 billion), dividends are far larger than capital spending or buybacks. Neither bought back much stock.
- Buy the pipeline (Merck, Pfizer, AbbVie). Merck spent about $10 billion on Verona and Pfizer about $7 billion on Metsera. Deals also leave later costs: AbbVie’s pre-tax income fell to $6.6 billion, mainly because of a $6.5 billion charge for revaluing contingent payments from past deals.
Using financial statements in AI and RAG
- Index the primary filing (earnings release, 10-K, or annual report) and record the fiscal year, currency, and GAAP or IFRS basis.
- Map each company’s line names to a common set. For example, MS&A, SI&A, and SG&A all go to SG&A.
- Flag where acquired IPR&D sits: on a separate line or inside R&D.
- Keep reported and adjusted figures apart. Adjusted (non-GAAP) results exclude items such as amortization and acquired IPR&D.
- Calculate ratios from stored figures rather than copying ratios from summaries.
Common mistakes
- Comparing R&D across companies without checking whether acquired IPR&D is included.
- Mixing GAAP and non-GAAP figures in one table.
- Comparing USD and CHF companies without noting the currency.
- Reading a low pre-tax margin as weak operations when it reflects one-off charges, as at AbbVie in 2025.
Checklist
- Primary filing indexed with year, currency, and basis
- Line names mapped consistently
- IPR&D treatment flagged
- Reported and adjusted figures separated
- Ratios recalculated from source figures
How AskDona helps
AskDona reads earnings releases, 10-Ks, and annual reports you load, and answers questions such as “how much did each competitor spend on acquired IPR&D?” with the exact line and page behind each figure.
Run a sample financial statement evidence check
AskDona shows the evidence; your finance and strategy teams decide.
Editor’s note. This article is general information, not investment advice. Income statement figures are reported GAAP (Roche: IFRS) from each company’s 2025 earnings release. Capital spending, dividends, and buybacks for Lilly, Merck, Pfizer, and AbbVie come from a secondary data provider. Percentages are our calculations.
FAQ
How much of revenue do big pharma companies spend on R&D? Between 15% (AbbVie) and 24% (Merck, including acquired IPR&D) in 2025.
Do they spend more on sales and marketing or on R&D? About the same overall. SG&A ran at 16 to 24% of revenue. Pfizer and AbbVie spent more on SG&A than on internal R&D.
What is acquired IPR&D? Upfront and milestone payments for drug candidates bought or licensed from others. AbbVie spent $5.0 billion on it in 2025.
Which company invested most in factories? Eli Lilly, with $7.8 billion of capital spending in 2025.
References
All pages opened and checked by October 30, 2026.
| Source | What it supports |
|---|---|
| Eli Lilly: Q4 2025 results | Lilly income statement |
| Pfizer: Q4 2025 earnings release (PDF) | Pfizer income statement, dividends, deals |
| Merck: Q4 and full-year 2025 results | Merck income statement |
| AbbVie: full-year 2025 results | AbbVie income statement, contingent consideration |
| Roche: 2025 annual results | Roche results |
| Roche Finance Report 2025 (mirror, PDF) | Roche IFRS lines, capex, dividends |
| stockanalysis.com: cash flow statements (Lilly) | Capex, dividends, buybacks (also MRK, PFE, ABBV pages) |
| Nasdaq: Lilly completes Verve acquisition | Verve deal |
| Merck: Verona Pharma completion | Verona deal |
| DCAT: AbbVie completes Capstan acquisition | Capstan deal |